Decapeptide Combi-Therapy of (resistant) steroidal cancers
Steroid-related cancers have the highest incidence among tumors and its market potential for Europe and U.S.A. is estimated to be at least US$ 2.4 bn p.a. Scientists at the University of Göttingen developed novel proprietary decapeptidic antagonists to target GnRH-II receptor (which is highly expressed in steroidal cancers like e.g. breast, ovarian, endometrium and prostate carcinomas), which could be used in a combination cancer therapy and which potentially could also be used to treat malignant melanoma.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Largest magnetic anisotropy of a molecule measured at BESSY II
At the Berlin synchrotron radiation source BESSY II, the largest magnetic anisotropy of a single molecule ever measured experimentally has been determined. The larger this anisotropy is, the better a…
Breaking boundaries: Researchers isolate quantum coherence in classical light systems
LSU quantum researchers uncover hidden quantum behaviors within classical light, which could make quantum technologies robust. Understanding the boundary between classical and quantum physics has long been a central question…
MRI-first strategy for prostate cancer detection proves to be safe
Active monitoring is a sufficiently safe option when prostate MRI findings are negative. There are several strategies for the early detection of prostate cancer. The first step is often a…